.jpg?format=webp&width=780)
The study involved a novel adenoviral-5 vector coding for VEGF, demonstrated enhanced local angiogenesis in preclinical models. During the study, patients received increasing doses of encoberminogene rezmadenovec, and the highest dose of 1×1011 viral particles appeared to be well tolerated. Improvements were observed in total exercise duration, myocardial perfusion deficit, and angina class. The therapy's safety and preliminary efficacy were evaluated over six months.
Like
Save
Share